Bvf INC/il
10% owner at ESSA Pharma Inc.; Other at Third Harmonic Bio, Inc.; Other at POINT Biopharma Global Inc., and 10 more
- Sold, on record
- $335M
- Dollars the filings state
- Form 4 sales
- 18
- Latest Aug 5, 2025
- Form 144 notices
- 0
- Proposed sales
- Companies
- 13
- Filed as an executive or holder
Companies
- ESSA Pharma Inc.10% owner
- Third Harmonic Bio, Inc.Other
- POINT Biopharma Global Inc.Other
- XOMA LTD /DE/10% owner
- INFINITY PHARMACEUTICALS, INC.10% owner
- ChemoCentryx, Inc.Other
- LGNDLIGAND PHARMACEUTICALS INC10% owner
- RIGLRIGEL PHARMACEUTICALS INC10% owner
- SUPERGEN INC10% owner
- ARQULE INC10% owner
- ADOLOR CORP10% owner
- DYNAVAX TECHNOLOGIES CORP10% owner
- CRISCURIS INC10% owner
Sales by reason
Form 4 sales per year, every sale on record.
Sales by company
- POINT Biopharma Global Inc.17.2M shares
- LGND6.1M shares
- CRIS3M shares
- INFINITY PHARMACEUTICALS, INC.2.3M shares
- ChemoCentryx, Inc.1.3M shares
- DYNAVAX TECHNOLOGIES CORP1.2M shares
- ADOLOR CORP1.1M shares
- Third Harmonic Bio, Inc.1M shares
- XOMA LTD /DE/651,700 shares
- ARQULE INC603,000 shares
- RIGL484,622 shares
- SUPERGEN INC170,000 shares
- ESSA Pharma Inc.156 shares
Shares sold, every Form 4 sale on record.
Timeline
- Aug 5, 2025No plan
Sold under 0.1% of their holdings
$293156 shares at $1.88
- Oct 29, 2024Unusual
Sold 85% of their holdings
$14.3M1M shares at $14.30
- Dec 18, 2023Unusual
Sold 100% of their holdings
$214M17.2M shares at $12.45
- Mar 31, 2021Unusual
Sold 89.6% of their holdings
$25M651,700 shares at $38.36
- Feb 11, 2021Unusual
INFINITY PHARMACEUTICALS, INC.
Sold 80.9% of their holdings
$12.1M2.3M shares at $5.37
- Nov 4, 2015Plan not stated
Sold 13.1% of their holdings
$2.5M360,000 shares at $7.00
- Jun 10, 2015Unusual
Sold 25.5% of their holdings
$8.6M955,700 shares at $9.00
- Nov 27, 2013Plan not stated
Sold 20.8% of their holdings
$30.2M527,505 shares at $57.27
- Nov 19, 2013Unusual
Sold 42.8% of their holdings
$1.3M484,622 shares at $2.64
- Apr 20, 2010Plan not stated
Sold 3% of their holdings
$604k170,000 shares at $3.56
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2025 | Oct 14, 2025 | ESSA Pharma Inc. | 10% owner | Tendered | 11.5M | 0 | SEC | ||
| Aug 5, 2025 | Aug 7, 2025 | ESSA Pharma Inc. | 10% owner | Exercised or settledPre-funded Warrants | 2.9M | 0 | SEC | ||
| Aug 5, 2025 | Aug 7, 2025 | ESSA Pharma Inc. | 10% owner | Exercised options | 2.9M | 560,808 | SEC | ||
| Aug 5, 2025 | Aug 7, 2025 | ESSA Pharma Inc. | 10% owner | Sold | 156 | $1.88 | $293 | 560,797 | SEC |
| Jun 11, 2025 | Jun 13, 2025 | OLMA | Director | AwardedStock Option (Right to buy) | 24,150 | 24,150 | SEC | ||
| Jun 5, 2025 | Jun 9, 2025 | MLTX | Director, 10% owner | AwardedOption to Buy | 6,682 | 6,682 | SEC | ||
| Dec 4, 2024 | Dec 4, 2024 | OLMA | Director | Returned to the company | 3.4M | 370,710 | SEC | ||
| Dec 4, 2024 | Dec 4, 2024 | OLMA | Director | AwardedPre-Funded Warrant | 5.8M | $3.84 | $22.4M | 313,548 | SEC |
| Oct 29, 2024 | Oct 31, 2024 | Third Harmonic Bio, Inc. | Other | Sold | 1M | $14.30 | $14.3M | 176,692 | SEC |
| May 9, 2024 | May 13, 2024 | ELDN | 10% owner | BoughtPre-funded Warrants to Purchase Common Stock | 5.9M | 232,068 | SEC | ||
| May 9, 2024 | May 13, 2024 | ELDN | 10% owner | Bought | 1.9M | 220,460 | SEC | ||
| Dec 18, 2023 | Dec 20, 2023 | POINT Biopharma Global Inc. | Other | Sold | 17.2M | $12.45 | $214M | 0 | SEC |
| Jun 15, 2022 | Jun 17, 2022 | KYMR | Director | AwardedStock Option (Right to Buy) | 12,000 | 12,000 | SEC | ||
| May 13, 2022 | May 16, 2022 | CGEM | 10% owner | Bought | 1.1M | $9.07 | $10.1M | 319,415 | SEC |
| May 6, 2022 | May 9, 2022 | KYMR | Director | Bought | 250,000 | $19.46 | $4.9M | 216,735 | SEC |
| Jan 31, 2022 | Jan 31, 2022 | KYMR | Other | Bought | 130,309 | $38.96 | $5.1M | 1.4M | SEC |
| Jan 7, 2022 | Jan 10, 2022 | Rain Oncology Inc. | 10% owner | Bought | 557,728 | $12.00 | $6.7M | 185,388 | SEC |
| Mar 31, 2021 | Apr 2, 2021 | XOMA LTD /DE/ | 10% owner | Sold | 651,700 | $38.36 | $25M | 149,975 | SEC |
| Feb 11, 2021 | Feb 16, 2021 | INFINITY PHARMACEUTICALS, INC. | 10% owner | Sold | 2.3M | $5.37 | $12.1M | 534,847 | SEC |
| Nov 4, 2020 | Nov 6, 2020 | CBIO | 10% owner | Bought | 1.3M | $2.60 | $3.3M | 630,453 | SEC |
| Oct 30, 2020 | Nov 3, 2020 | CBIO | 10% owner | Bought | 932,612 | $2.75 | $2.6M | 544,363 | SEC |
| Sep 22, 2020 | Sep 24, 2020 | FIVE PRIME THERAPEUTICS INC | 10% owner | Bought | 32 | $3.80 | $122 | 541,116 | SEC |
| Sep 10, 2020 | Sep 14, 2020 | Merus N.V. | 10% owner | Bought | 189,651 | $11.10 | $2.1M | 372,526 | SEC |
| May 14, 2020 | May 18, 2020 | FIVE PRIME THERAPEUTICS INC | 10% owner | Bought | 293,587 | $4.10 | $1.2M | 541,084 | SEC |
| Oct 25, 2019 | Oct 25, 2019 | FIVE PRIME THERAPEUTICS INC | 10% owner | Bought | 169,370 | $3.74 | $634k | 346,627 | SEC |
| Dec 13, 2018 | Dec 13, 2018 | XOMA LTD /DE/ | 10% owner | Bought | 36,463 | $14.46 | $527k | 693,541 | SEC |
| Nov 28, 2018 | Nov 30, 2018 | INFINITY PHARMACEUTICALS, INC. | 10% owner | Bought | 100,000 | $1.30 | $130k | 6.5M | SEC |
| Nov 21, 2018 | Nov 21, 2018 | INFINITY PHARMACEUTICALS, INC. | 10% owner | Bought | 1.5M | $1.37 | $2M | 1.3M | SEC |
| May 11, 2017 | May 11, 2017 | ALPINE IMMUNE SCIENCES, INC. | 10% owner | Bought | 109,034 | $2.33 | $254k | 178,428 | SEC |
| Dec 20, 2016 | Dec 20, 2016 | INFINITY PHARMACEUTICALS, INC. | 10% owner | Bought | 654,921 | $1.31 | $856k | 621,547 | SEC |
| Nov 5, 2015 | Nov 5, 2015 | ChemoCentryx, Inc. | Other | Other | 2.4M | 0 | SEC | ||
| Nov 4, 2015 | Nov 5, 2015 | ChemoCentryx, Inc. | Other | Sold | 360,000 | $7.00 | $2.5M | 2.4M | SEC |
| Jun 10, 2015 | Jun 11, 2015 | ChemoCentryx, Inc. | 10% owner | Sold | 955,700 | $9.00 | $8.6M | 2.8M | SEC |
| Dec 17, 2014 | Dec 17, 2014 | Oncothyreon Inc. | 10% owner | Bought | 378,444 | $1.82 | $688k | 3.3M | SEC |
| Nov 27, 2013 | Nov 29, 2013 | LGND | 10% owner | Sold | 527,505 | $57.27 | $30.2M | 2M | SEC |
| Nov 19, 2013 | Nov 20, 2013 | RIGL | 10% owner | Sold | 484,622 | $2.64 | $1.3M | 646,559 | SEC |
| Nov 1, 2013 | Nov 1, 2013 | ChemoCentryx, Inc. | 10% owner | Bought | 336,225 | $4.99 | $1.7M | 1.1M | SEC |
| Oct 3, 2013 | Oct 7, 2013 | ChemoCentryx, Inc. | 10% owner | Bought | 109,425 | $5.49 | $601k | 524,011 | SEC |
| Dec 14, 2012 | Dec 18, 2012 | LGND | 10% owner | Bought | 5,386 | $18.63 | $100k | 2.1M | SEC |
| Oct 21, 2011 | Oct 25, 2011 | LGND | 10% owner | Bought | 4,600 | $13.93 | $64k | 1.7M | SEC |
| Jul 26, 2011 | Jul 28, 2011 | CAPS | 10% owner | Bought | 18,400 | $0.25 | $5k | 3.7M | SEC |
| Jul 11, 2011 | Jul 13, 2011 | CAPS | 10% owner | Bought | 9,000 | $0.25 | $2k | 3.2M | SEC |
| Jun 30, 2011 | Jul 5, 2011 | CAPS | 10% owner | Bought | 4,700 | $0.25 | $1k | 3.2M | SEC |
| Apr 20, 2010 | Apr 21, 2010 | SUPERGEN INC | 10% owner | Sold | 170,000 | $3.56 | $604k | 5.6M | SEC |
| Apr 5, 2010 | Apr 7, 2010 | ARQULE INC | 10% owner | Sold | 603,000 | $6.13 | $3.7M | 4.2M | SEC |
| Feb 9, 2010 | Feb 9, 2010 | FACET BIOTECH CORP | 10% owner | Bought | 39,200 | $15.48 | $607k | 3.9M | SEC |
| Jan 29, 2010 | Jan 29, 2010 | FACET BIOTECH CORP | 10% owner | Bought | 271,600 | $15.69 | $4.3M | 3.7M | SEC |
| Sep 21, 2009 | Sep 21, 2009 | ADOLOR CORP | 10% owner | Sold | 402,000 | $1.67 | $672k | 4.5M | SEC |
| Sep 10, 2009 | Sep 11, 2009 | DYNAVAX TECHNOLOGIES CORP | 10% owner | Sold | 1.2M | $2.76 | $3.3M | 4.3M | SEC |
| Aug 24, 2009 | Aug 26, 2009 | LGND | 10% owner | Sold | 4.6M | $2.57 | $11.7M | 10.6M | SEC |
Sales and notices (18)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | Aug 7, 2025 | ESSA Pharma Inc. | 10% owner | Form 4 sale | 156 | $293 | 0.0% | No plan | SEC |
| Oct 29, 2024 | Oct 31, 2024 | Third Harmonic Bio, Inc. | Other | Form 4 sale | 1M | $14.3M | 85.0% | Unusual | SEC |
| Dec 18, 2023 | Dec 20, 2023 | POINT Biopharma Global Inc. | Other | Form 4 sale | 17.2M | $214M | 100.0% | Unusual | SEC |
| Mar 31, 2021 | Apr 2, 2021 | XOMA LTD /DE/ | 10% owner | Form 4 sale | 651,700 | $25M | 89.6% | Unusual | SEC |
| Feb 11, 2021 | Feb 16, 2021 | INFINITY PHARMACEUTICALS, INC. | 10% owner | Form 4 sale | 2.3M | $12.1M | 80.9% | Unusual | SEC |
| Nov 4, 2015 | Nov 5, 2015 | ChemoCentryx, Inc. | Other | Form 4 sale | 360,000 | $2.5M | 13.1% | Plan not stated | SEC |
| Jun 10, 2015 | Jun 11, 2015 | ChemoCentryx, Inc. | 10% owner | Form 4 sale | 955,700 | $8.6M | 25.5% | Unusual | SEC |
| Nov 27, 2013 | Nov 29, 2013 | LGND | 10% owner | Form 4 sale | 527,505 | $30.2M | 20.8% | Plan not stated | SEC |
| Nov 19, 2013 | Nov 20, 2013 | RIGL | 10% owner | Form 4 sale | 484,622 | $1.3M | 42.8% | Unusual | SEC |
| Apr 20, 2010 | Apr 21, 2010 | SUPERGEN INC | 10% owner | Form 4 sale | 170,000 | $604k | 3.0% | Plan not stated | SEC |
| Apr 5, 2010 | Apr 7, 2010 | ARQULE INC | 10% owner | Form 4 sale | 603,000 | $3.7M | 12.5% | Plan not stated | SEC |
| Sep 21, 2009 | Sep 21, 2009 | ADOLOR CORP | 10% owner | Form 4 sale | 402,000 | $672k | 8.2% | Plan not stated | SEC |
| Sep 10, 2009 | Sep 11, 2009 | DYNAVAX TECHNOLOGIES CORP | 10% owner | Form 4 sale | 1.2M | $3.3M | 22.1% | Plan not stated | SEC |
| Aug 24, 2009 | Aug 26, 2009 | LGND | 10% owner | Form 4 sale | 4.6M | $11.7M | 30.0% | Unusual | SEC |
| Jul 14, 2009 | Jul 15, 2009 | ADOLOR CORP | 10% owner | Form 4 sale | 725,500 | $1.2M | 11.7% | Plan not stated | SEC |
| Jul 1, 2009 | Jul 6, 2009 | LGND | 10% owner | Form 4 sale | 142,700 | $424k | 0.9% | Plan not stated | SEC |
| Jun 29, 2009 | Jun 29, 2009 | LGND | 10% owner | Form 4 sale | 829,265 | $2.4M | 5.1% | Plan not stated | SEC |
| Apr 27, 2009 | Apr 29, 2009 | CRIS | 10% owner | Form 4 sale | 3M | $3.4M | 33.3% | Unusual | SEC |